Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Women who are diagnosed with ductal carcinoma in situ (DCIS) outside the National Health Service breast screening programme are around four times as likely to develop invasive breast cancer and to die from breast cancer than women in the general population, finds a University of Oxford study published by the British Medical Journal (BMJ)

Mammogram showing breast cancer tumour © Shutterstock

This increased risk lasted for at least 25 years after diagnosis, suggesting that ductal carcinoma in situ (DCIS) survivors may benefit from regular checks for at least three decades, say the researchers.

Ductal carcinoma in situ (DCIS) is a disease where malignant breast cells are found but have not spread beyond the milk ducts. It isn’t immediately life-threatening, but can increase the risk of developing invasive breast cancer in the future.

DCIS is often detected by the NHS breast screening programme, but some diagnoses occur outside the programme, either because women are not in the eligible 50-70 year age range, or they did not respond to a screening invitation, or because their DCIS developed between screens.

An earlier study by the same authors found that screen-detected Ductal carcinoma in situ is associated with more than twice the risk of invasive breast cancer and breast cancer related death than the general population, but long term rates after non-screen detected disease are still unclear.

 

Read the full story on the University of Oxford website.

 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience